Quarterly Outlook
Fixed Income Outlook: Bonds Hit Reset. A New Equilibrium Emerges
Althea Spinozzi
Head of Fixed Income Strategy
Chief Investment Strategist
Summary: We are updating our methodology on the bubble stocks basket introduced in early January as too many of the stocks had very high equity valuations but because they were strong companies. In this updated 'bubble stocks' basket we now require negative earnings expectations over the next 12 months. Many of the names are still the same, but a lot new ones have entered our list. If news or data begin to disappoint against expectations and interest rates continue to climb higher on more inflation, our reflation call for this year, then the most aggressively valued stocks could come under severe pressure.
Following our introduction of the reflation theme which we expect to dominate financial markets over the next 12-18 months, we talked about bubble stocks and introduced 40 stocks that had bubble like characteristics. While all 40 stocks are aggressively valued, some of them have high valuations due to industry specific characteristics (exchange and certain software companies). We have been thinking about the bubble stocks basket since and have chosen to update the methodology. Some of the stocks are the same, but many new stocks are on the list, but we think this list is much better.
Our selection universe is still stocks listed on the exchanges in North America, Western Europe, Japan, Hong Kong, Singapore, and Australia. We filter on market cap (above $ 2bn) and require that stocks have a negative 12-month forward expected earnings per share, and that the 12-month forward EV/Sales (enterprise value to sales) ratio is above 8. Our of an initial universe of 3,776 stocks (those with market cap above $2bn), 194 stocks have negative earnings expectations and a high equity valuation on their expected revenue. Of these stocks, we select the top 40 stocks on market cap (see list below).
Name | Domicile | Mkt Cap (USD mn.) | 12M Fwd EPS | 12M Fwd EV/Sales | Diff to PT (%) |
Kuaishou Technology | China | 213,499 | -0.85 | 16.2 | -14.2 |
Sea Ltd | Singapore | 140,384 | -1.26 | 17.3 | -15.5 |
Airbnb Inc | United States | 130,635 | -1.31 | 28.1 | -29.2 |
NIO Inc | China | 94,795 | -1.59 | 18.0 | 7.9 |
Snowflake Inc | United States | 84,570 | -0.87 | 71.5 | 0.1 |
DoorDash Inc | United States | 67,743 | -0.19 | 17.6 | -22.9 |
Roku Inc | United States | 59,111 | -0.26 | 23.1 | -21.4 |
Bilibili Inc | China | 51,601 | -4.76 | 18.2 | -29.8 |
Teladoc Health Inc | United States | 41,124 | -0.30 | 20.3 | -9.9 |
XPeng Inc | China | 37,228 | -2.41 | 15.0 | 13.9 |
Affirm Holdings Inc | United States | 34,499 | -0.89 | 39.7 | -5.8 |
BeiGene Ltd | China | 34,490 | -9.78 | 35.8 | -15.1 |
Unity Software Inc | United States | 34,299 | -0.35 | 32.7 | 13.7 |
Plug Power Inc | United States | 32,156 | -0.18 | 68.1 | 15.0 |
Seagen Inc | United States | 31,016 | -0.11 | 15.9 | 14.0 |
Cloudflare Inc | United States | 28,050 | -0.08 | 46.1 | 2.6 |
Splunk Inc | United States | 27,486 | -0.21 | 10.8 | 20.7 |
MongoDB Inc | United States | 25,201 | -0.98 | 34.1 | -5.1 |
Exact Sciences Corp | United States | 24,752 | -1.14 | 13.3 | 6.4 |
GSX Techedu Inc | China | 24,455 | -3.34 | 11.8 | -32.1 |
Farfetch Ltd | United Kingdom | 23,465 | -0.66 | 10.3 | -11.9 |
DraftKings Inc | United States | 23,186 | -1.16 | 26.5 | 4.5 |
GDS Holdings Ltd | China | 20,998 | -0.15 | 18.6 | -1.8 |
10X Genomics Inc | United States | 20,458 | -0.32 | 38.9 | -16.1 |
Argenx SE | Netherlands | 19,397 | -10.72 | 105.2 | -12.6 |
Alnylam Pharmaceuticals Inc | United States | 19,214 | -4.77 | 21.0 | 3.6 |
Ping An Healthcare and Technology Co Ltd | China | 18,942 | -0.91 | 11.6 | 2.7 |
Innovent Biologics Inc | China | 18,305 | -0.61 | 24.0 | 9.0 |
Guardant Health Inc | United States | 16,826 | -1.50 | 40.5 | -6.9 |
Zai Lab Ltd | China | 15,781 | -2.52 | 87.5 | -12.5 |
Kingsoft Cloud Holdings Ltd | China | 15,710 | -2.56 | 9.6 | -22.4 |
Yatsen Holding Ltd | China | 15,665 | -1.17 | 10.7 | -7.0 |
Oak Street Health Inc | United States | 15,461 | -0.46 | 11.1 | 0.8 |
C3.ai Inc | United States | 15,370 | -0.79 | 69.6 | -12.5 |
Bill.com Holdings Inc | United States | 15,319 | -0.19 | 57.4 | -6.7 |
Canopy Growth Corp | Canada | 15,279 | -0.90 | 24.2 | -8.4 |
Appian Corp | United States | 15,229 | -0.40 | 43.3 | -52.9 |
Avalara Inc | United States | 14,770 | -0.16 | 21.3 | 18.3 |
Elastic NV | United States | 14,429 | -0.44 | 20.6 | -1.0 |
Cree Inc | United States | 14,240 | -0.59 | 21.3 | -21.1 |
Aggregate / mean | 1,565,141 | 30.7 | -6.5 |
Source: Bloomberg and Saxo Grop
The red thread is that the list is dominated by US and Chinese stocks with the majority within biotechnology, software, media, and gaming. The combined market value for this group is stunningly $1.6trn but even more usual, the average price target is 6.5% below the current price which is something that rarely happens in equity markets as equity analysts typically have a positive bias in their recommendations and price targets. The average forward EV/Sales ratio is 30.7x which is around 10 times higher than the S&P 500 which is one of the most expensive equity indices in the world.
While January performance in equities was driven green transformation and biotechnology stocks, this month so far has been about e-commerce and bubble stocks with the latter segment up 11.2% month-to-date. In our team, we have tried the past couple of days to strike a tone of caution with financial conditions maxing out to the positive side and thus we think reality could begin to disappoint a bit against expectations. If interest rates continue higher, which we expect due to reflation, then the bubble stocks presented here pose a significant downside risk.
Disclaimer
The Saxo Bank Group entities each provide execution-only service and access to Analysis permitting a person to view and/or use content available on or via the website. This content is not intended to and does not change or expand on the execution-only service. Such access and use are at all times subject to (i) The Terms of Use; (ii) Full Disclaimer; (iii) The Risk Warning; (iv) the Rules of Engagement and (v) Notices applying to Saxo News & Research and/or its content in addition (where relevant) to the terms governing the use of hyperlinks on the website of a member of the Saxo Bank Group by which access to Saxo News & Research is gained. Such content is therefore provided as no more than information. In particular no advice is intended to be provided or to be relied on as provided nor endorsed by any Saxo Bank Group entity; nor is it to be construed as solicitation or an incentive provided to subscribe for or sell or purchase any financial instrument. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. As such no Saxo Bank Group entity will have or be liable for any losses that you may sustain as a result of any investment decision made in reliance on information which is available on Saxo News & Research or as a result of the use of the Saxo News & Research. Orders given and trades effected are deemed intended to be given or effected for the account of the customer with the Saxo Bank Group entity operating in the jurisdiction in which the customer resides and/or with whom the customer opened and maintains his/her trading account. Saxo News & Research does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws.
Please read our disclaimers:
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)
- Full disclaimer (https://www.home.saxo/en-gb/legal/disclaimer/saxo-disclaimer)